BAKER BROS. ADVISORS LP Q3 2017 Filing
Filed November 14, 2017
Portfolio Value
$12.3T
Holdings
121
Report Date
Q3 2017
Filing Type
13F-HR
All Holdings (121 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | INCYIncyte Corporation | 34,230,323 | $4.0T | 32.41% | |
| 2 | SGENEURSeattle Genetics, Inc. | 45,725,556 | $2.5T | 20.18% | |
| 3 | ALXNAlexion Pharmaceuticals, Inc. | 8,553,864 | $1.2T | 9.73% | |
| 4 | ACADACADIA Pharmaceuticals Inc. | 25,819,768 | $972.6B | 7.89% | |
| 5 | BMRNBioMarin Pharmaceutical Inc. | 5,905,673 | $549.6B | 4.46% | |
| 6 | —Genomic Health, Inc. | 13,780,480 | $442.2B | 3.59% | |
| 7 | ONCBeiGene, Ltd. | 3,898,431 | $403.3B | 3.27% | |
| 8 | —DBV Technologies S.A. | 5,509,560 | $233.8B | 1.90% | |
| 9 | —Aquinox Pharmaceuticals, Inc. | 10,934,154 | $155.2B | 1.26% | |
| 10 | —Advanced Accelerator Applications S.A. | 2,243,262 | $151.7B | 1.23% | |
| 11 | —Spark Therapeutics, Inc. | 1,384,130 | $123.4B | 1.00% | |
| 12 | ASNDAscendis Pharma A/S | 2,348,840 | $85.1B | 0.69% | |
| 13 | AMRNAmarin Corporation plc | 22,669,509 | $79.3B | 0.64% | |
| 14 | —AveXis, Inc. | 775,000 | $75.0B | 0.61% | |
| 15 | BCRXBioCryst Pharmaceuticals, Inc. | 13,997,172 | $73.3B | 0.59% | |
| 16 | NVTA1EURInvitae Corporation | 7,288,300 | $68.3B | 0.55% | |
| 17 | ARRYEURArray BioPharma Inc. | 5,213,528 | $64.1B | 0.52% | |
| 18 | —Achaogen, Inc. | 3,886,878 | $62.0B | 0.50% | |
| 19 | —Bellicum Pharmaceuticals, Inc. | 5,032,313 | $58.1B | 0.47% | |
| 20 | EX9Exelixis, Inc. | 2,082,012 | $50.4B | 0.41% | |
| 21 | HRTXHeron Therapeutics, Inc. | 2,787,992 | $45.0B | 0.37% | |
| 22 | NVAX 3.75 02/01/23Novavax, Inc. | 88,500,000 | $39.5B | 0.32% | |
| 23 | NBIXNeurocrine Biosciences, Inc. | 616,682 | $37.8B | 0.31% | |
| 24 | —bluebird bio, Inc. | 241,441 | $33.2B | 0.27% | |
| 25 | GBYSangamo Therapeutics, Inc. | 2,113,376 | $31.7B | 0.26% | |
| 26 | —Acorda Therapeutics, Inc. | 35,083,000 | $31.6B | 0.26% | |
| 27 | —Abeona Therapeutics Inc. | 1,684,364 | $28.7B | 0.23% | |
| 28 | HALOHalozyme Therapeutics, Inc. | 1,581,424 | $27.5B | 0.22% | |
| 29 | CERSCerus Corporation | 9,745,209 | $26.6B | 0.22% | |
| 30 | MRTXEURMirati Therapeutics, Inc. | 2,269,198 | $26.5B | 0.22% | |
| 31 | GLPGGalapagos NV | 259,894 | $26.4B | 0.21% | |
| 32 | NTLAIntellia Therapeutics, Inc. | 1,062,120 | $26.4B | 0.21% | |
| 33 | SG7Sage Therapeutics, Inc. | 405,485 | $25.3B | 0.20% | |
| 34 | CBAYUSDCymaBay Therapeutics, Inc. | 2,991,775 | $24.1B | 0.20% | |
| 35 | —Progenics Pharmaceuticals, Inc. | 3,150,808 | $23.2B | 0.19% | |
| 36 | MRUSMerus N.V. | 1,160,014 | $23.0B | 0.19% | |
| 37 | —Idera Pharmaceuticals, Inc. | 10,306,757 | $23.0B | 0.19% | |
| 38 | —NeuroDerm Ltd. | 571,667 | $22.2B | 0.18% | |
| 39 | IM8NInsmed Incorporated | 700,000 | $21.8B | 0.18% | |
| 40 | IMGNEURImmunoGen, Inc. | 2,688,489 | $20.6B | 0.17% | |
| 41 | XNCRXencor, Inc. | 872,072 | $20.0B | 0.16% | |
| 42 | —Aimmune Therapeutics, Inc. | 673,908 | $16.7B | 0.14% | |
| 43 | —Ignyta, Inc. | 1,299,199 | $16.0B | 0.13% | |
| 44 | —MyoKardia, Inc. | 355,264 | $15.2B | 0.12% | |
| 45 | BMRN 0.599 08/01/24BioMarin Pharmaceutical Inc. | 15,000,000 | $15.2B | 0.12% | |
| 46 | AERIEURAerie Pharmaceuticals, Inc. | 299,356 | $14.5B | 0.12% | |
| 47 | —Foamix Pharmaceuticals Ltd. | 2,466,702 | $13.7B | 0.11% | |
| 48 | —BioMarin Pharmaceutical Inc. | 12,228,000 | $13.6B | 0.11% | |
| 49 | CPRXCatalyst Pharmaceuticals, Inc. | 5,102,153 | $12.9B | 0.10% | |
| 50 | —Acorda Therapeutics, Inc. | 519,500 | $12.3B | 0.10% | |
| 51 | —Newlink Genetics Corporation | 1,007,273 | $10.3B | 0.08% | |
| 52 | LGNDLigand Pharmaceuticals Incorporated | 73,386 | $10.0B | 0.08% | |
| 53 | ITCIEURIntra-Cellular Therapies, Inc. | 609,166 | $9.6B | 0.08% | |
| 54 | —Loxo Oncology, Inc. | 96,062 | $8.8B | 0.07% | |
| 55 | ASMBAssembly Biosciences, Inc. | 250,000 | $8.7B | 0.07% | |
| 56 | AGIOAgios Pharmaceuticals, Inc. | 128,666 | $8.6B | 0.07% | |
| 57 | —Syros Pharmaceuticals, Inc. | 574,835 | $8.5B | 0.07% | |
| 58 | —Achillion Pharmaceuticals, Inc. | 1,856,637 | $8.3B | 0.07% | |
| 59 | —ContraFect Corporation | 7,153,076 | $7.9B | 0.06% | |
| 60 | GLYCEURGlycoMimetics, Inc. | 563,312 | $7.9B | 0.06% | |
| 61 | —Nabriva Therapeutics plc | 938,235 | $7.7B | 0.06% | |
| 62 | ALKSAlkermes plc | 150,251 | $7.6B | 0.06% | |
| 63 | —GW Pharmaceuticals plc | 75,000 | $7.6B | 0.06% | |
| 64 | VNDAVanda Pharmaceuticals Inc. | 423,884 | $7.6B | 0.06% | |
| 65 | —Aegerion Pharmaceuticals, Inc. | 9,517,000 | $7.6B | 0.06% | |
| 66 | —Dimension Therapeutics, Inc. | 1,251,881 | $7.5B | 0.06% | |
| 67 | —Stemline Therapeutics, Inc. | 633,497 | $7.0B | 0.06% | |
| 68 | MGNXMacroGenics, Inc. | 363,676 | $6.7B | 0.05% | |
| 69 | RIGLUSDRigel Pharmaceuticals, Inc. | 2,518,882 | $6.4B | 0.05% | |
| 70 | TTPHEURTetraphase Pharmaceuticals, Inc. | 935,000 | $6.4B | 0.05% | |
| 71 | —Spring Bank Pharmaceuticals, Inc. | 373,144 | $6.3B | 0.05% | |
| 72 | XLRNAcceleron Pharma Inc. | 163,900 | $6.1B | 0.05% | |
| 73 | —Aevi Genomic Medicine, Inc. | 4,546,426 | $5.7B | 0.05% | |
| 74 | AGLEUSDAeglea BioTherapeutics, Inc. | 1,137,872 | $5.6B | 0.05% | |
| 75 | —Array BioPharma Inc. | 3,000,000 | $5.4B | 0.04% | |
| 76 | —La Jolla Pharmaceutical Company | 154,675 | $5.4B | 0.04% | |
| 77 | SELBUSDSelecta Biosciences, Inc. | 289,809 | $5.3B | 0.04% | |
| 78 | VYGRVoyager Therapeutics, Inc. | 237,014 | $4.9B | 0.04% | |
| 79 | —Epizyme, Inc. | 232,481 | $4.4B | 0.04% | |
| 80 | —Clementia Pharmaceuticals Inc. | 250,000 | $4.2B | 0.03% | |
| 81 | BDQMAlbireo Pharma, Inc. | 200,000 | $4.2B | 0.03% | |
| 82 | —Inotek Pharmaceuticals Corporation | 5,000,000 | $3.9B | 0.03% | |
| 83 | ANABAnaptysBio, Inc. | 111,386 | $3.9B | 0.03% | |
| 84 | —Adamas Pharmaceuticals, Inc. | 172,630 | $3.7B | 0.03% | |
| 85 | —Versartis, Inc. | 1,437,214 | $3.5B | 0.03% | |
| 86 | —Tonix Pharmaceuticals Holdings Corp. | 699,500 | $3.2B | 0.03% | |
| 87 | —Akari Therapeutics plc | 496,901 | $3.1B | 0.02% | |
| 88 | NTRANatera, Inc. | 228,676 | $2.9B | 0.02% | |
| 89 | OVIDOvid Therapeutics Inc. | 333,333 | $2.9B | 0.02% | |
| 90 | —Ra Pharmaceuticals, Inc. | 177,952 | $2.6B | 0.02% | |
| 91 | MDGLMadrigal Pharmaceuticals, Inc. | 57,762 | $2.6B | 0.02% | |
| 92 | —Protalix BioTherapeutics, Inc. | 3,423,000 | $2.6B | 0.02% | |
| 93 | —Trevena, Inc. | 950,000 | $2.4B | 0.02% | |
| 94 | KPTIEURKaryopharm Therapeutics Inc. | 216,990 | $2.4B | 0.02% | |
| 95 | NVAXNovavax, Inc. | 2,000,000 | $2.3B | 0.02% | |
| 96 | ARGXargenx SE | 100,000 | $2.3B | 0.02% | |
| 97 | TREURTrillium Therapeutics Inc. | 413,697 | $2.1B | 0.02% | |
| 98 | KRYSKrystal Biotech, Inc. | 200,000 | $2.0B | 0.02% | |
| 99 | DVAXDynavax Technologies Corporation | 75,000 | $1.6B | 0.01% | |
| 100 | JNCEEURJounce Therapeutics, Inc. | 100,000 | $1.6B | 0.01% |
Page 1 of 2Next